OBJECTIVE: Growing literature supports good survival expectancies in bladder cancer (BCa) patients affected by clinical node metastases (cN+) treated with multimodal therapy. We evaluated the role of adjuvant chemotherapy in cN+BCa patients treated with radical cystectomy (RC) and pelvic lymph node dissection (PLND) without neoadjuvant chemotherapy (NAC). METHODS: We evaluated a total of 192 patients with BCa and cN+. All patients were treated with RC and PLND without NAC between 2001 and 2013. Kaplan-Meier analyses and Cox regression analyses were used to assess the impact of adjuvant chemotherapy (ACT) on recurrence, cancer-specific mortality (CSM) and overall mortality (OM) after surgery. RESULTS: Overall, 99 patients (51.6%) were found without node metastases at RC, while 18 (9.4%), 58 (30.2%) and 17 (8.9%) patients were found pN1, pN2 and pN3, respectively. With a median follow-up of 48 months, in cN+ patients we recorded 5-year recurrence, CSM and OM of 55, 53 and 51%, respectively. Overall, 36 (18.8%) patients were treated with adjuvant chemotherapy. At univariable analyses, ACT was associated with improved overall survival [Hazard ratio (HR): 0.42, confidence interval (CI) 0.20-0.86, p = 0.02) in pN+ subgroup only. These results were confirmed at multivariable analyses, where ACT was associated with improved CSS (HR: 0.45, CI 0.21-0.89, p = 0.03) and OS (HR: 0.37, CI 0.17-0.81, p = 0.01). CONCLUSIONS: We report good survival outcomes in cN+ patients treated with RC. The use of ACT after surgery increases survival expectancies, especially in those patients with pathological node disease. Our data need to be further evaluated in prospective setting.
OBJECTIVE: Growing literature supports good survival expectancies in bladder cancer (BCa) patients affected by clinical node metastases (cN+) treated with multimodal therapy. We evaluated the role of adjuvant chemotherapy in cN+BCa patients treated with radical cystectomy (RC) and pelvic lymph node dissection (PLND) without neoadjuvant chemotherapy (NAC). METHODS: We evaluated a total of 192 patients with BCa and cN+. All patients were treated with RC and PLND without NAC between 2001 and 2013. Kaplan-Meier analyses and Cox regression analyses were used to assess the impact of adjuvant chemotherapy (ACT) on recurrence, cancer-specific mortality (CSM) and overall mortality (OM) after surgery. RESULTS: Overall, 99 patients (51.6%) were found without node metastases at RC, while 18 (9.4%), 58 (30.2%) and 17 (8.9%) patients were found pN1, pN2 and pN3, respectively. With a median follow-up of 48 months, in cN+ patients we recorded 5-year recurrence, CSM and OM of 55, 53 and 51%, respectively. Overall, 36 (18.8%) patients were treated with adjuvant chemotherapy. At univariable analyses, ACT was associated with improved overall survival [Hazard ratio (HR): 0.42, confidence interval (CI) 0.20-0.86, p = 0.02) in pN+ subgroup only. These results were confirmed at multivariable analyses, where ACT was associated with improved CSS (HR: 0.45, CI 0.21-0.89, p = 0.03) and OS (HR: 0.37, CI 0.17-0.81, p = 0.01). CONCLUSIONS: We report good survival outcomes in cN+ patients treated with RC. The use of ACT after surgery increases survival expectancies, especially in those patients with pathological node disease. Our data need to be further evaluated in prospective setting.
Authors: J P Stein; G Lieskovsky; R Cote; S Groshen; A C Feng; S Boyd; E Skinner; B Bochner; D Thangathurai; M Mikhail; D Raghavan; D G Skinner Journal: J Clin Oncol Date: 2001-02-01 Impact factor: 44.544
Authors: Marco Moschini; Alessandro Morlacco; Alberto Briganti; Brian Hu; Renzo Colombo; Francesco Montorsi; Igor Frank; Siamak Daneshmand; R Jeffrey Karnes Journal: Eur Urol Focus Date: 2016-11-23
Authors: Giacomo Novara; Robert S Svatek; Pierre I Karakiewicz; Eila Skinner; Vincenzo Ficarra; Yves Fradet; Yair Lotan; Hendrik Isbarn; Umberto Capitanio; Patrick J Bastian; Wassim Kassouf; Hans-Martin Fritsche; Jonathan I Izawa; Derya Tilki; Colin P Dinney; Seth P Lerner; Mark Schoenberg; Bjoern G Volkmer; Arthur I Sagalowsky; Shahrokh F Shariat Journal: J Urol Date: 2010-06 Impact factor: 7.450
Authors: Philip L Ho; Daniel L Willis; Jeevitha Patil; Lianchun Xiao; Stephen B Williams; Jonathan J Melquist; Karen Tart; Sahil Parikh; Jay B Shah; Scott E Delacroix; Neema Navai; Arlene Siefker-Radtke; Colin P Dinney; Louis L Pisters; Ashish M Kamat Journal: Urol Oncol Date: 2015-10-01 Impact factor: 3.498
Authors: Maxine Sun; Firas Abdollah; Marco Bianchi; Quoc-Dien Trinh; Shahrokh F Shariat; Claudio Jeldres; Zhe Tian; Jens Hansen; Alberto Briganti; Markus Graefen; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: Eur J Cancer Date: 2011-12-21 Impact factor: 9.162
Authors: Marco Moschini; R Jeffrey Karnes; Giorgio Gandaglia; Stefano Luzzago; Paolo Dell'Oglio; Martina S Rossi; Ettore di Trapani; Giovanni La Croce; Rocco Damiano; Andrea Salonia; Shahrokh F Shariat; Francesco Montorsi; Alberto Briganti; Andrea Gallina; Renzo Colombo Journal: Urology Date: 2015-12-09 Impact factor: 2.649
Authors: Kamran Zargar-Shoshtari; Homayoun Zargar; Yair Lotan; Jay B Shah; Bas W van Rhijn; Siamak Daneshmand; Philippe E Spiess; Peter C Black Journal: J Urol Date: 2015-07-21 Impact factor: 7.450
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Matthew D Galsky; Kristian Stensland; John P Sfakianos; Reza Mehrazin; Michael Diefenbach; Nihal Mohamed; Che-Kai Tsao; Paolo Boffetta; Peter Wiklund; William K Oh; Madhu Mazumdar; Bart Ferket Journal: J Clin Oncol Date: 2016-06-06 Impact factor: 44.544
Authors: J Alfred Witjes; Thierry Lebret; Eva M Compérat; Nigel C Cowan; Maria De Santis; Harman Maxim Bruins; Virginia Hernández; Estefania Linares Espinós; James Dunn; Mathieu Rouanne; Yann Neuzillet; Erik Veskimäe; Antoine G van der Heijden; Georgios Gakis; Maria J Ribal Journal: Eur Urol Date: 2016-06-30 Impact factor: 20.096
Authors: Daan J Reesink; Ewoudt M W van de Garde; Paul van der Nat; Diederik M Somford; Maartje Los; Simon Horenblas; Harm H E van Melick Journal: World J Urol Date: 2022-04-10 Impact factor: 4.226
Authors: Michał Frączek; Hubert Kamecki; Anna Kamecka; Roman Sosnowski; Katarzyna Sklinda; Marcin Czarniecki; Leszek Królicki; Jerzy Walecki Journal: Transl Androl Urol Date: 2018-10